Drug intelligence / Profile preview

EA-2

Development stage: Preclinical
Lead developer: Endo Axiom
Modality: Nanoparticles → Drug Delivery Systems
Administration: Oral

Overview

EA-2 is a preclinical-stage tolerogenic biologic developed by Endo Axiom, primarily aimed at the prevention of Type 1 diabetes onset. The therapeutic utilizes a quantum-dot-enabled delivery platform designed for oral administration. Its mechanism of action involves the targeted delivery of tolerogenic signals to hepatic antigen-presenting cells (APCs), which are central to the induction of systemic immune tolerance. By promoting an immune-tolerant environment in the liver, EA-2 is designed to prevent the autoimmune destruction of pancreatic beta cells. The program has demonstrated efficacy in NOD (non-obese diabetic) mouse models and is also being explored as a platform for other conditions, such as peanut allergy.

Other names: Autoimmune prevention programme

Beyond the preview

Go deeper on EA-2.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on EA-2.

Explore the full profile